Tag: Clinical Trials

AYAs enrolled in trials increased from 9.5 to 14.0 percent after launch of National Clinical Trials Network

Phase 1 trial testing both intranasal and intramuscular administration

More drugs with high abuse potential made it through the development process than new drugs with low abuse potential

Gap seen in cardiovascular, psychiatry, and cancer trial participation versus national prevalence disease data

Trial was the first to test a drug meant to delay or halt mental decline in people who have a genetic predisposition

Numbers of new patient accruals and newly activated trials decreased early on, followed by progressive recovery

Proportion of SWOG trial participants who had Medicaid insurance increased by 20 percent per year after ACA Medicaid expansion

40 percent of respondents reported that care team had not discussed trials; concerns about side effects, effectiveness limit participation

The phase 1 trial is expected to last four years and enroll 40 participants

Extrapolation of the findings from pivotal clinical trials to the approved indication most common for disease severity